Role of Viral Chemokine Receptors in Cytomegalovirus Latency.

病毒趋化因子受体在巨细胞病毒潜伏期中的作用。

基本信息

  • 批准号:
    8680118
  • 负责人:
  • 金额:
    $ 34.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-05 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Reactivation of Human Cytomegalovirus (HCMV) from latency is the most common infectious complication in bone marrow transplant patients, with significant morbidity and mortality. Very little is known about the viral/host interactions governing the establishment and maintenance of long term HCMV infection. The long-term goal is to identify the viral and host mechanisms that lead to the development of CMV latency. The objective of this proposal is to determine the role of the CMV-encoded chemokine receptors in the establishment of latency in progenitor myeloid lineage cells and to identify the host signaling pathways that promote CMV establishment of latency. The central hypothesis is that the CMV-encoded chemokine receptors activate host signaling pathways which aid in the establishment of latency during in vivo infection. Project Summary: Our hypothesis is based on strong preliminary data which demonstrates that murine CMV (MCMV) lacking M33 does not efficiently establish latent infection and that M33-deficient viruses which express the HCMV-encoded chemokine receptors, UL33 or US28, complements this latency defect in vivo. Three specific aims will be pursued: 1) Identify the myeloid lineage cell type which requires M33 for the establishment and/or maintenance of CMV latency in vivo, 2) Identify the mechanisms underlying the role of M33 during infection in monocytes, and 3) Identify the M33-mediated signaling pathway (s) required for establishment and/or maintenance of CMV latency. This aim will utilize specific M33 mutant viruses coupled with microarray analysis to identify signaling pathways which are modulated by M33 and US28. The approach is innovative, and uses a multifaceted approach to identify the host and viral factors involved in the establishment and/or maintenance of CMV latency in myeloid lineage cells. The proposed research is significant, because it is expected to lead to the development of therapeutic strategies aimed at preventing CMV latency and complications due to reactivation of latent CMV. Relevance to Public Health: The new knowledge obtained will lead to the prevention of CMV latency and reactivation in immunocompromised patients, such transplant patients, neonates, and AIDS patients, where CMV infection leads to significant morbidity and mortality.
描述(由申请方提供):人巨细胞病毒(HCMV)潜伏期再激活是骨髓移植患者最常见的感染性并发症,具有显著的发病率和死亡率。很少有人知道病毒/宿主的相互作用,建立和维持长期HCMV感染。长期目标是确定导致CMV潜伏期发展的病毒和宿主机制。本提案的目的是确定CMV编码的趋化因子受体在祖细胞髓系细胞中建立潜伏期的作用,并确定促进CMV建立潜伏期的宿主信号传导途径。中心假设是CMV编码的趋化因子受体激活宿主信号传导途径,这有助于在体内感染期间建立潜伏期。项目概要:我们的假设是基于强有力的初步数据,这些数据表明缺乏M33的鼠巨细胞病毒(MCMV)无法有效建立潜伏感染,而表达巨细胞病毒编码的趋化因子受体UL 33或US 28的M33缺陷病毒可以补充体内的这种潜伏缺陷。将追求三个具体目标:1)鉴定需要M33以建立和/或维持体内CMV潜伏期的髓系细胞类型,2)鉴定单核细胞感染期间M33作用的潜在机制,和3)鉴定建立和/或维持CMV潜伏期所需的M33介导的信号传导途径。这一目标将利用特定的M33突变病毒与微阵列分析相结合,以确定由M33和US 28调节的信号通路。该方法是创新的,并且使用多方面的方法来鉴定参与骨髓谱系细胞中CMV潜伏期的建立和/或维持的宿主和病毒因素。拟议的研究是重要的,因为它有望导致旨在预防CMV潜伏期和由于潜伏CMV再激活引起的并发症的治疗策略的发展。与公共卫生的相关性:获得的新知识将导致预防免疫功能低下患者中的CMV潜伏期和再激活,例如移植患者、新生儿和AIDS患者,其中CMV感染导致显著的发病率和死亡率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rhonda D Cardin其他文献

A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.
用于治疗 COVID-19 的第二代口服 SARS-CoV-2 主要蛋白酶抑制剂临床候选药物。
  • DOI:
    10.1021/acs.jmedchem.3c02469
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    C. Allerton;Joel T. Arcari;L. Aschenbrenner;Melissa Avery;B. Bechle;Mohammad Amin Behzadi;B. Boras;Leanne M. Buzon;Rhonda D Cardin;Natasha R Catlin;Anthony A Carlo;Karen J. Coffman;A. Dantonio;Li Di;Heather Eng;Kathleen A. Farley;Rose Ann Ferre;Steven S Gernhardt;Scott A Gibson;S. Greasley;Siennah R. Greenfield;B. Hurst;A. Kalgutkar;Emi Kimito;L. Lanyon;Gabrielle H Lovett;Yajing Lian;Wei Liu;Luis A Martínez Alsina;Stephen Noell;R. Obach;Dafydd R Owen;Nandini C Patel;Devendra K Rai;M. Reese;H. Rothan;Sylvie K. Sakata;M. Sammons;Jean G Sathish;Raman Sharma;C. Steppan;J. Tuttle;P. Verhoest;Liuqing Wei;Qingyi Yang;Irina Yurgelonis;Yuao Zhu
  • 通讯作者:
    Yuao Zhu

Rhonda D Cardin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rhonda D Cardin', 18)}}的其他基金

Center for Experimental Infectious Disease Research
实验传染病研究中心
  • 批准号:
    9265314
  • 财政年份:
    2014
  • 资助金额:
    $ 34.29万
  • 项目类别:
Role of Viral Chemokine Receptors in Cytomegalovirus Latency.
病毒趋化因子受体在巨细胞病毒潜伏期中的作用。
  • 批准号:
    8867123
  • 财政年份:
    2012
  • 资助金额:
    $ 34.29万
  • 项目类别:
Role of Viral Chemokine Receptors in Cytomegalovirus Latency
病毒趋化因子受体在巨细胞病毒潜伏期中的作用
  • 批准号:
    9284685
  • 财政年份:
    2012
  • 资助金额:
    $ 34.29万
  • 项目类别:
Role of Viral Chemokine Receptors in Cytomegalovirus Latency.
病毒趋化因子受体在巨细胞病毒潜伏期中的作用。
  • 批准号:
    8235473
  • 财政年份:
    2012
  • 资助金额:
    $ 34.29万
  • 项目类别:
Role of Viral Chemokine Receptors in Cytomegalovirus Latency.
病毒趋化因子受体在巨细胞病毒潜伏期中的作用。
  • 批准号:
    8502610
  • 财政年份:
    2012
  • 资助金额:
    $ 34.29万
  • 项目类别:
ROLE OF ALPHA GENE PRODUCTS IN CMV LATENCY
ALPHA 基因产物在 CMV 潜伏期中的作用
  • 批准号:
    2058561
  • 财政年份:
    1993
  • 资助金额:
    $ 34.29万
  • 项目类别:
ROLE OF ALPHA GENE PRODUCTS IN CMV LATENCY
ALPHA 基因产物在 CMV 潜伏期中的作用
  • 批准号:
    3030576
  • 财政年份:
    1992
  • 资助金额:
    $ 34.29万
  • 项目类别:
ROLE OF ALPHA GENE PRODUCTS IN CMV LATENCY
ALPHA 基因产物在 CMV 潜伏期中的作用
  • 批准号:
    3030575
  • 财政年份:
    1992
  • 资助金额:
    $ 34.29万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 34.29万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 34.29万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 34.29万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 34.29万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 34.29万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 34.29万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 34.29万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 34.29万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 34.29万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 34.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了